Electronic components manufacturer CTS Corporation (NYSE: CTS) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 4.6% year on year to $149.6 million. The company’s full-year revenue guidance of $585 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP profit of $0.77 per share was 17.9% above analysts’ consensus estimates.

Is now the time to buy CTS? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

CTS’s third quarter was marked by robust growth in diversified end markets and execution on margin expansion initiatives, resulting in a positive market reaction. Management attributed the improved quality of earnings to rising demand in medical and industrial segments, as well as effective cost discipline. CEO Pratik Trivedi highlighted that “strong execution drove record profitability and robust cash generation,” citing a 42.2% gross margin and notable expansion in the company’s end-market mix. The company’s focus on operational performance and a favorable product mix contributed significantly to these results.

Looking ahead, CTS’s updated full-year guidance reflects management’s confidence in sustained demand from diversified markets and the accretive potential of its recent Millar acquisition. CEO Pratik Trivedi emphasized the strategic importance of expanding into advanced medical sensing and industrial automation, mentioning, “We see compelling opportunities to accelerate growth by leveraging complementary technologies and expanding customer relationships.” Management also noted that the ongoing integration of Millar and continued investment in high-value sensing technologies are expected to support long-term revenue and margin growth.

Key insights from management’s remarks

Management attributed Q3 performance to the ongoing shift toward diversified end markets, product mix improvements, and the acquisition of Millar, which strengthens CTS’s position in medical and industrial sensing applications.

• Diversified markets momentum: CTS’s diversified end markets grew 7% year-over-year, now comprising 60% of total sales. This shift was fueled by broad demand across medical, industrial, and aerospace, reducing reliance on the transportation sector and supporting higher-quality earnings.

• Medical segment acceleration: The medical end market delivered 21% year-over-year growth, driven by demand for advanced diagnostics and therapeutic applications. Management referenced partnerships with leading medical OEMs and highlighted ongoing product wins in pacemaker and imaging applications as key contributors.

• Industrial recovery continues: Industrial sales increased 7% year-over-year, benefiting from trends such as automation, data center infrastructure, and energy efficiency. New customer wins and healthy bookings across industrial printing, HVAC, and automation solutions reinforced the ongoing recovery in this segment.

• Aerospace and defense backlog: Aerospace and Defense sales were volatile but showed a strong book-to-bill ratio of 1.91, indicating robust future demand. Management pointed to expanding roles in naval sonar and undersea warfare applications as strategic opportunities.

• Millar acquisition integration: The recent acquisition of Millar expands CTS’s capabilities in high-value pressure and chemical sensing, particularly in medical markets. Management expects the deal to drive revenue growth and be accretive to gross margin, though noted EBITDA accretion will take time as synergies develop.

Drivers of future performance

Management’s outlook centers on sustaining momentum in diversified markets, integrating Millar, and navigating uncertainties in transportation and global supply chains.

• Millar acquisition impact: Management expects the integration of Millar to expand CTS’s presence in medical and industrial sensing, with the acquisition seen as a driver for long-term revenue growth and gross margin accretion. However, EBITDA contribution will ramp gradually, with full earnings accretion expected by the second half of 2027.

• Stable industrial and medical demand: CTS anticipates continued healthy demand in industrial and medical end markets, underpinned by secular trends such as automation, data center growth, and increased demand for advanced diagnostics. The company is positioned to benefit from favorable demographics and ongoing product innovation in these segments.

• Transportation market headwinds: Management cautioned that global light vehicle production could remain flat or decline due to tariffs, geopolitical risks, and consumer uncertainty. CTS is focused on agility in adapting pricing and cost structures in response to these challenges.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will be closely monitoring (1) the pace and success of Millar’s integration and its impact on CTS’s product portfolio, (2) the sustainability of margin improvements as end-market mix evolves, and (3) the company’s ability to maintain growth in industrial and medical segments despite transportation market headwinds. Execution on new product launches and customer wins will also be key indicators of ongoing momentum.

CTS currently trades at $62.40, up from $53.92 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).

Our favorite stocks right now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.